Breadcrumbs

Multiple myeloma - haematology

Protocol Administration at chemotherapy unit level Review date
AL amyloidosis melphalan and dexamethasone oral Medium Cycle 1 Low Cycle 2 onwards if patient tolerates March 2022
Multiple myeloma and AL amyloidosis CTD (CYCLOPHOSPHamide thalidomide dexamethasone) oral Low September 2022
Multiple myeloma carfilzomib and dexamethasone Medium September 2021
Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) weekly Low September 2022
Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) Low September 2022
Multiple myeloma daratumumab Medium June 2022
Multiple myeloma daratumumab maintenance Medium - cycle 1Low - cycle 2 onwards as per clinician discretion September 2022
Multiple myeloma DRd (daratumumab lenalidomide dexamethasone) Medium - cycle 1 Low - cycle 2 onwards as per clinician discretion September 2022
Multiple myeloma DT-PACE (dexamethasone thalidomide cISplatin DOXOrubicin CYCLOPHOSPHamide etoposide) High September 2022
Multiple myeloma thalidomide and dexamethasone oral High September 2022
Multiple myeloma D-VMP (daratumumab bortezomib melphalan prednisolone) Medium - cycle 1 Low - cycle 2 onwards as per clinician discretion September 2022
Multiple myeloma ixazomib lenalidomide and dexamethasone oral
Low
September 
2022
Multiple myeloma lenalidomide and dexamethasone oral Low September 2022
Multiple myeloma and AL amyloidosis CTD (CYCLOPHOSPHamide thalidomide dexamethasone) oral High September 2019
Multiple myeloma MPT (melphalan prednisolone thalidomide) oral Low September 2022
Multiple myeloma pomalidomide and dexamethasone oral Low September 2022

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top